HUP0203485A2 - Purinszármazékok - Google Patents
PurinszármazékokInfo
- Publication number
- HUP0203485A2 HUP0203485A2 HU0203485A HUP0203485A HUP0203485A2 HU P0203485 A2 HUP0203485 A2 HU P0203485A2 HU 0203485 A HU0203485 A HU 0203485A HU P0203485 A HUP0203485 A HU P0203485A HU P0203485 A2 HUP0203485 A2 HU P0203485A2
- Authority
- HU
- Hungary
- Prior art keywords
- compounds
- production
- group
- methyl
- optionally substituted
- Prior art date
Links
- 229940083251 peripheral vasodilators purine derivative Drugs 0.000 title abstract 2
- 125000000561 purinyl group Chemical class N1=C(N=C2N=CNC2=C1)* 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 238000004519 manufacturing process Methods 0.000 abstract 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 238000002360 preparation method Methods 0.000 abstract 2
- 125000000547 substituted alkyl group Chemical group 0.000 abstract 2
- ZWVFKYGWXZGSDM-UHFFFAOYSA-N O=S(=O)NCC1=NC=C2NC=NC2=N1 Chemical class O=S(=O)NCC1=NC=C2NC=NC2=N1 ZWVFKYGWXZGSDM-UHFFFAOYSA-N 0.000 abstract 1
- 239000002465 adenosine A2a receptor agonist Substances 0.000 abstract 1
- 125000002947 alkylene group Chemical group 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 abstract 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 1
- 239000013067 intermediate product Substances 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 125000001624 naphthyl group Chemical group 0.000 abstract 1
- 125000000962 organic group Chemical group 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 150000003212 purines Chemical class 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/167—Purine radicals with ribosyl as the saccharide radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Reproductive Health (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Otolaryngology (AREA)
- Gynecology & Obstetrics (AREA)
- Oncology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychiatry (AREA)
Abstract
A találmány új purinszármazékokra vonatkozik. Közelebbről a találmányúj N-[(purin-2-il)metil]szulfonamid-származékokra és ezek előállításieljárására, továbbá az említett vegyületek előállítása soránhasznosított köztitermékekre, az említett vegyületeket tartalmazógyógyászati készítményekre és az említett vegyületeknek gyógyászatikészítmények előállítására való alkalmazására vonatkozik. A találmányszerinti vegyületek mint adenozin A2a receptor agonistákhasznosíthatók. (I) általános képletükben R1 jelentése hidrogénatomvagy adott esetben helyettesített alkilcsoport; A jelentése kémiaikötés vagy alkiléncsoport; R2 jelentése hidrogénatom vagy adottesetben szubsztituált alkil-, cikloalkil-, fenil- vagy naftilcsoportvagy különböző szerves csoportok és R7 jelentése metil-, etil- vagyciklopropilmetilcsoport. Ó
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9924361.0A GB9924361D0 (en) | 1999-10-14 | 1999-10-14 | Purine derivatives |
| PCT/IB2000/001446 WO2001027131A1 (en) | 1999-10-14 | 2000-10-06 | Purine derivatives |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HUP0203485A2 true HUP0203485A2 (hu) | 2003-03-28 |
| HUP0203485A3 HUP0203485A3 (en) | 2005-02-28 |
Family
ID=10862758
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU0203485A HUP0203485A3 (en) | 1999-10-14 | 2000-10-06 | Purine derivatives |
Country Status (43)
Families Citing this family (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0003960D0 (en) | 2000-02-18 | 2000-04-12 | Pfizer Ltd | Purine derivatives |
| US6921753B2 (en) | 2000-06-27 | 2005-07-26 | Pfizer Inc | Purine derivatives |
| GB0015727D0 (en) * | 2000-06-27 | 2000-08-16 | Pfizer Ltd | Purine derivatives |
| GB0022695D0 (en) | 2000-09-15 | 2000-11-01 | Pfizer Ltd | Purine Derivatives |
| TW200519106A (en) | 2003-05-02 | 2005-06-16 | Novartis Ag | Organic compounds |
| US20050033044A1 (en) | 2003-05-19 | 2005-02-10 | Bristol-Myers Squibb Pharma Company | Methods for preparing 2-alkynyladenosine derivatives |
| GB0401334D0 (en) | 2004-01-21 | 2004-02-25 | Novartis Ag | Organic compounds |
| EP1728793B1 (en) | 2004-03-26 | 2016-02-03 | Sumitomo Dainippon Pharma Co., Ltd. | 9-substituted 8-oxoadenine compound |
| TWI346109B (en) * | 2004-04-30 | 2011-08-01 | Otsuka Pharma Co Ltd | 4-amino-5-cyanopyrimidine derivatives |
| GB0411056D0 (en) | 2004-05-18 | 2004-06-23 | Novartis Ag | Organic compounds |
| PT1758596E (pt) * | 2004-05-26 | 2010-06-23 | Inotek Pharmaceuticals Corp | Derivados de purina como agonistas do receptor de adenosina a1 e processos para a sua utilização |
| RU2007114887A (ru) * | 2004-09-20 | 2008-10-27 | Инотек Фармасьютикалз Корпорейшн (Us) | Производные пурина и способы их применения |
| GB0424284D0 (en) | 2004-11-02 | 2004-12-01 | Novartis Ag | Organic compounds |
| GB0426164D0 (en) | 2004-11-29 | 2004-12-29 | Novartis Ag | Organic compounds |
| GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
| JP5006330B2 (ja) | 2005-10-21 | 2012-08-22 | ノバルティス アーゲー | Ｉｌ１３に対するヒト抗体および治療的使用 |
| CN101321460A (zh) * | 2005-11-30 | 2008-12-10 | 伊诺泰克制药公司 | 嘌呤衍生物及其用法 |
| GB0601951D0 (en) | 2006-01-31 | 2006-03-15 | Novartis Ag | Organic compounds |
| AR060607A1 (es) * | 2006-04-21 | 2008-07-02 | Novartis Ag | Derivados de purina,composiciones farmaceuticas que los contienen, metodo de preparacion y usos en enfermedades obstructivas o inflamatorias de las vias respiratorias. |
| US8138172B2 (en) | 2006-07-05 | 2012-03-20 | Astrazeneca Ab | 8-oxoadenine derivatives acting as modulators of TLR7 |
| US20090286779A1 (en) | 2006-09-29 | 2009-11-19 | Novartis Ag | Pyrazolopyrimidines as lipid kinase inhibitors |
| CN101522682A (zh) | 2006-10-30 | 2009-09-02 | 诺瓦提斯公司 | 作为抗炎剂的杂环化合物 |
| TW200831105A (en) * | 2006-12-14 | 2008-08-01 | Astrazeneca Ab | Novel compounds |
| US20100105652A1 (en) * | 2007-03-02 | 2010-04-29 | Glaxo Group Limited | Purines as cysteine protease inhibitors |
| ES2457316T3 (es) * | 2007-03-19 | 2014-04-25 | Astrazeneca Ab | Compuestos 8-oxo-adenina 9 sustituidos como moduladores del receptor similares a toll (TLR7) |
| ES2373616T3 (es) * | 2007-03-19 | 2012-02-07 | Astrazeneca Ab | Compuestos de 8-oxo-adenina 9 sustituidos como moduladores del receptor de tipo toll (tlr7). |
| AR065784A1 (es) * | 2007-03-20 | 2009-07-01 | Dainippon Sumitomo Pharma Co | Derivados de 8-oxo adenina,medicamentos que los contienen y usos como agentes terapeuticos para enfermedades alergicas, antivirales o antibacterianas. |
| US8044056B2 (en) | 2007-03-20 | 2011-10-25 | Dainippon Sumitomo Pharma Co., Ltd. | Adenine compound |
| JP5400763B2 (ja) * | 2007-05-08 | 2014-01-29 | アストラゼネカ・アクチエボラーグ | 免疫調節特性を有するイミダゾキノリン類 |
| PE20091156A1 (es) | 2007-12-17 | 2009-09-03 | Astrazeneca Ab | Sales de (3-{[[3-(6-amino-2-butoxi-8-oxo-7,8-dihidro-9h-purin-9-il)propil](3-morfolin-4-ilpropil)amino]metil}fenil)acetato de metilo |
| BRPI0906838A2 (pt) | 2008-01-11 | 2015-07-14 | Novartis Ag | Pirimidinas como inibidores de quinase |
| US20110054168A1 (en) * | 2008-01-17 | 2011-03-03 | Ayumu Kurimoto | Method for preparing adenine compound |
| KR20100125245A (ko) | 2008-01-17 | 2010-11-30 | 다이닛본 스미토모 세이야꾸 가부시끼가이샤 | 아데닌 화합물의 제조 방법 |
| US20110281917A1 (en) | 2009-01-29 | 2011-11-17 | Darrin Stuart | Substituted Benzimidazoles for the Treatment of Astrocytomas |
| US8389526B2 (en) | 2009-08-07 | 2013-03-05 | Novartis Ag | 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives |
| EA201200260A1 (ru) | 2009-08-12 | 2012-09-28 | Новартис Аг | Гетероциклические гидразоны и их применение для лечения рака и воспаления |
| GEP201706639B (en) | 2009-08-17 | 2017-03-27 | Intellikine Llc | Heterocyclic compounds and uses thereof |
| IN2012DN01453A (hu) | 2009-08-20 | 2015-06-05 | Novartis Ag | |
| JP2013512859A (ja) * | 2009-12-03 | 2013-04-18 | 大日本住友製薬株式会社 | トール様受容体（ｔｌｒ）を介して作用するイミダゾキノリン |
| EP2523669B1 (en) | 2010-01-11 | 2016-12-07 | Inotek Pharmaceuticals Corporation | Combination, kit and method of reducing intraocular pressure |
| AU2011230580A1 (en) | 2010-03-26 | 2012-10-11 | Inotek Pharmaceuticals Corporation | Method of reducing intraocular pressure in humans using N6 -cyclopentyladenosine (CPA), CPA derivatives or prodrugs thereof |
| WO2012034095A1 (en) | 2010-09-09 | 2012-03-15 | Irm Llc | Compounds and compositions as trk inhibitors |
| UY33597A (es) | 2010-09-09 | 2012-04-30 | Irm Llc | Compuestos y composiciones como inhibidores de la trk |
| CN103370317B (zh) | 2010-12-16 | 2015-10-07 | 阿斯利康(瑞典)有限公司 | 可用于治疗的咪唑并[4,5-c]喹啉-1-基衍生物 |
| WO2012080730A1 (en) | 2010-12-17 | 2012-06-21 | Astrazeneca Ab | Purine derivatives |
| EP2673277A1 (en) | 2011-02-10 | 2013-12-18 | Novartis AG | [1, 2, 4]triazolo [4, 3 -b]pyridazine compounds as inhibitors of the c-met tyrosine kinase |
| WO2012116237A2 (en) | 2011-02-23 | 2012-08-30 | Intellikine, Llc | Heterocyclic compounds and uses thereof |
| JP5959541B2 (ja) | 2011-02-25 | 2016-08-02 | ノバルティス アーゲー | Ｔｒｋ阻害剤としてのピラゾロ［１，５−ａ］ピリジン |
| WO2013038362A1 (en) | 2011-09-15 | 2013-03-21 | Novartis Ag | 6 - substituted 3 - (quinolin- 6 - ylthio) - [1,2,4] triazolo [4, 3 -a] pyradines as tyrosine kinase |
| EP2793893A4 (en) | 2011-11-23 | 2015-07-08 | Intellikine Llc | IMPROVED TREATMENT REGIMES USING MTOR INHIBITORS |
| PL2807178T3 (pl) | 2012-01-26 | 2017-12-29 | Inotek Pharmaceuticals Corporation | Bezwodne polimorfy azotanu (2R,3S,4R,5R)-5-(6-(cyklopentyloamino)-9H-puryn-9-ylo)-3,4-dihydroksytetrahydrofuran-2-ylo)metylu i sposoby ich wytwarzania |
| ES2894830T3 (es) | 2012-04-03 | 2022-02-16 | Novartis Ag | Productos combinados con inhibidores de tirosina·cinasa y su uso |
| MX2015013234A (es) | 2013-03-15 | 2016-04-15 | Inotek Pharmaceuticals Corp | Formulaciones oftalmicas. |
| WO2014151147A1 (en) | 2013-03-15 | 2014-09-25 | Intellikine, Llc | Combination of kinase inhibitors and uses thereof |
| WO2015084804A1 (en) | 2013-12-03 | 2015-06-11 | Novartis Ag | Combination of mdm2 inhibitor and braf inhibitor and their use |
| WO2016011658A1 (en) | 2014-07-25 | 2016-01-28 | Novartis Ag | Combination therapy |
| ES2831416T3 (es) | 2014-07-31 | 2021-06-08 | Novartis Ag | Terapia de combinación de un inhibidor de MET y un inhibidor de EGFR |
| TW202140550A (zh) | 2020-01-29 | 2021-11-01 | 瑞士商諾華公司 | 使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5536419A (en) * | 1978-09-08 | 1980-03-14 | Yamasa Shoyu Co Ltd | 2-substituted adenosine derivative and its preparation |
| AU8276187A (en) * | 1986-10-31 | 1988-05-25 | Warner-Lambert Company | Selected n6-substituted adenosines having selective a2 binding activity |
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| US5877180A (en) * | 1994-07-11 | 1999-03-02 | University Of Virginia Patent Foundation | Method for treating inflammatory diseases with A2a adenosine receptor agonists |
| GB9414193D0 (en) | 1994-07-14 | 1994-08-31 | Glaxo Group Ltd | Compounds |
| GB9711643D0 (en) | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
| CA2347512C (en) * | 1998-10-16 | 2005-12-06 | Pfizer Inc. | Adenine derivatives |
| GB9913932D0 (en) | 1999-06-15 | 1999-08-18 | Pfizer Ltd | Purine derivatives |
-
1999
- 1999-10-14 GB GBGB9924361.0A patent/GB9924361D0/en not_active Ceased
-
2000
- 2000-09-26 PA PA20008503601A patent/PA8503601A1/es unknown
- 2000-10-06 TR TR2002/01001T patent/TR200201001T2/xx unknown
- 2000-10-06 EE EEP200200194A patent/EE200200194A/xx unknown
- 2000-10-06 AU AU74412/00A patent/AU771531B2/en not_active Ceased
- 2000-10-06 PL PL00354880A patent/PL354880A1/xx not_active Application Discontinuation
- 2000-10-06 GE GE4727A patent/GEP20043324B/en unknown
- 2000-10-06 HU HU0203485A patent/HUP0203485A3/hu unknown
- 2000-10-06 CN CNB008141762A patent/CN1166678C/zh not_active Expired - Fee Related
- 2000-10-06 CZ CZ20021179A patent/CZ20021179A3/cs unknown
- 2000-10-06 JP JP2001530349A patent/JP3994008B2/ja not_active Expired - Fee Related
- 2000-10-06 CA CA002387533A patent/CA2387533C/en not_active Expired - Fee Related
- 2000-10-06 EA EA200200360A patent/EA004985B1/ru not_active IP Right Cessation
- 2000-10-06 OA OA1200200103A patent/OA12060A/en unknown
- 2000-10-06 SK SK474-2002A patent/SK4742002A3/sk unknown
- 2000-10-06 IL IL14833100A patent/IL148331A0/xx unknown
- 2000-10-06 AP APAP/P/2002/002480A patent/AP2002002480A0/en unknown
- 2000-10-06 WO PCT/IB2000/001446 patent/WO2001027131A1/en active IP Right Grant
- 2000-10-06 DE DE60026861T patent/DE60026861T2/de not_active Expired - Fee Related
- 2000-10-06 MX MXPA02003750A patent/MXPA02003750A/es active IP Right Grant
- 2000-10-06 ES ES00962773T patent/ES2257317T3/es not_active Expired - Lifetime
- 2000-10-06 NZ NZ517294A patent/NZ517294A/en unknown
- 2000-10-06 KR KR1020027004766A patent/KR20030022758A/ko active IP Right Grant
- 2000-10-06 EP EP00962773A patent/EP1220862B1/en not_active Expired - Lifetime
- 2000-10-06 AT AT00962773T patent/ATE321065T1/de not_active IP Right Cessation
- 2000-10-06 BR BR0014760-5A patent/BR0014760A/pt not_active IP Right Cessation
- 2000-10-10 GT GT200000170A patent/GT200000170A/es unknown
- 2000-10-12 EC EC2000003713A patent/ECSP003713A/es unknown
- 2000-10-12 MY MYPI20004789A patent/MY141512A/en unknown
- 2000-10-12 GT GT200000173A patent/GT200000173A/es unknown
- 2000-10-12 CO CO00077983A patent/CO5261621A1/es not_active Application Discontinuation
- 2000-10-13 AR ARP000105422A patent/AR026052A1/es unknown
- 2000-10-13 PE PE2000001099A patent/PE20010753A1/es not_active Application Discontinuation
- 2000-10-13 SV SV2000000199A patent/SV2002000199A/es unknown
- 2000-10-13 TN TNTNSN00203A patent/TNSN00203A1/fr unknown
- 2000-10-16 US US09/688,497 patent/US6448236B1/en not_active Expired - Fee Related
-
2002
- 2002-02-26 IS IS6287A patent/IS6287A/is unknown
- 2002-03-11 CR CR6607A patent/CR6607A/es not_active Application Discontinuation
- 2002-04-02 BG BG106567A patent/BG106567A/xx unknown
- 2002-04-08 ZA ZA200202725A patent/ZA200202725B/en unknown
- 2002-04-09 MA MA26591A patent/MA26829A1/fr unknown
- 2002-04-12 NO NO20021751A patent/NO20021751L/no not_active Application Discontinuation
- 2002-04-12 HR HR20020325A patent/HRP20020325A2/xx not_active Application Discontinuation
-
2003
- 2003-01-07 HK HK03100163.8A patent/HK1047942B/zh not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUP0203485A2 (hu) | Purinszármazékok | |
| HUP0203483A2 (hu) | Purinszármazékok | |
| TR200401622T4 (tr) | Pürin türevleri | |
| HUP9802323A2 (hu) | Pirimidinszármazékok, eljárás előállításukra és az ezeket tartalmazó gyógyászati készítmények | |
| SE0102438D0 (sv) | New compounds | |
| TR200103607T2 (tr) | Pürin Türevleri | |
| AP2002002598A0 (en) | Purine derivatives. | |
| SE0102439D0 (sv) | New compounds | |
| HUP9903671A2 (hu) | Gonadotropint leadó hormonok antagonistái,e vegyületeket tartalmazó gyógyászati készítmények,valamint azok előállítása | |
| DE60120197D1 (de) | Verfahren zur herstellung von 2-amino-6-(alkyl)amino-4,5,6,7-tetrahydrobenzothiazolen | |
| HUP0102453A2 (hu) | Adenozinszármazékok, alkalmazásuk és e vegyületeket tartalmazó gyógyászati készítmények | |
| HUP0400561A2 (hu) | 3-Aroilindol-származékok és a vegyületek CB2 receptor agonistaként való alkalmazása, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények | |
| BR0214142A (pt) | Derivados e intermediários de n-adamantilmetila como composições farmacêuticas e processos para sua preparação | |
| HUP0302771A2 (hu) | Nitrozo-difenilamin-származékok, eljárás az előállításukra, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
| HUP0303868A2 (hu) | Helyettesített triazol-diamin-származékok mint kináz inhibitorok és alkalmazások gyógyszerkészítmények előállítására | |
| BR0008770A (pt) | Derivado de pirimidina, processo para a preparação de um derivado de pirimidina, processo para a produção de um efeito anti-câncer em um animal de sangue quente, uso de um derivado de pirimidina, e, composição farmacêutica | |
| BR0206433A (pt) | Composto, composição farmacêutica, processo para a prepapação de um composto, e, uso de um composto | |
| DE69128231T2 (de) | Heterozyklische Alkylamine, Verfahren zu ihrer Herstellung und pharmazeutische Zusammensetzungen die sie enthalten | |
| HUP0002311A2 (hu) | Ergolinszármazékok és szomatosztatin receptorként való alkalmazásuk | |
| HUP9701270A2 (hu) | Neuraminsavszármazékok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk gyógyszerkészítmények előállítására | |
| AR036176A1 (es) | Un derivado de fenil-acetamido-tiazol, un procedimiento para su preparacion, una composicion farmaceutica que lo comprende, un producto o kit que los comprende, y un metodo que utiliza dicho derivado | |
| YU86601A (sh) | Derivati purina, postupak za njihovo dobijanje i farmaceutski preparati koji ih sadrže | |
| ATE89561T1 (de) | 3,4-disubstituierte-2-azetidinon-derivate und verfahren zu ihrer herstellung. | |
| HUP0300183A2 (hu) | Sejt adhézió inhibítorként ható szubsztituált purinszármazékok | |
| ATE107298T1 (de) | 3-aminochroman-derivate, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzungen. |